The wide variation (40% to 91%) in COX-2 over-expression in ovarian cancers in the published studies may be due to study design (all types of ovarian cancer versus EOCs or specific histological sub-type), disease stage, tumour grade and histological sub-type, genetic make-up, patients' characteristics such as age, among other reasons. This evidence concerns the gene PTGS2 and neoplasm.